Sofinnova Investments’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Sofinnova Investments’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-572,297	Closed	-$18.3M	–	72
2022 Q1	$18.3M	Buy	572,297 +360,016	+170%	+$10.3M	1.39%	18
2021 Q4	$4.62M	Buy	212,281 +5,717	+3%	+$126K	0.27%	56
2021 Q3	$4.53M	Buy	206,564 +204,064	+8,163%	+$4.08M	0.27%	58
2021 Q2	$49K	Buy	+2,500	New	+$45.4K	﹤0.01%	67
2018 Q2	–	Sell	-2,453	Closed	-$203K	–	73
2018 Q1	$203K	Buy	+2,453	New	+$278K	0.03%	48

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sofinnova Investments's SRRA Position: Q2 2022 in Review

Sofinnova Investments sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 572,297 shares — an estimated $18.3M sold.

Sofinnova Investments first reported a position in SRRA in Q1 2018 and held it in 5 quarters. The position peaked at $18.3M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

Sofinnova Investments reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Sofinnova Investments sold 572,297 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $18.3M.
Sofinnova Investments first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Sofinnova Investments's Sierra Oncology, Inc. Common Stock position peaked at $18.3M in Q1 2022.
109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.